http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
1 online resource (xviii, 424 pages) : illustrations.
This issue reviews the role of metals in neurodegenerative diseases; including Parkinson's and Huntington's disease; restless leg syndrome and NBIA disorders; and Wilson's disease and manganese and calcium accumulation disorders. An update on advances in neuroimaging and pathology of metal related disease is also presented. This volume of International Review of Neurobiology brings together cutting-edge research on metal related neurodegenerative disease. It reviews the role of metals in neurodegenerative diseases, including Parkinson's and Huntington's disease; restless leg syndrome and NBIA disorders; and Wilson's disease and manganese and calcium accumulation disorders. An update on advances in neuroimaging and pathology of metal related disease is also presented.
Front Cover; Metal Related Neurodegenerative Disease; Copyright; Contents; Contributors; Preface; Editorial: Metal-Related Neurological Disorders: Several New Genes and Better Understanding; Reference; Chapter One: The Relevance of Metals in the Pathophysiology of Neurodegeneration, Pathological Considerations; 1. Introduction; 2. The Role of Specific Metals in Neurodegeneration; 2.1. The role of iron; 2.1.1. Alzheimer disease; 2.1.2. Parkinson disease; 2.1.3. Multiple sclerosis; 2.1.4. Other neurodegenerative disorders; 2.2. The role of aluminum; 2.3. The role of copper
2.4. The role of zinc2.5. The role of manganese; 3. Conclusions and Future Perspectives; References; Chapter Two: Pantothenate Kinase-Associated Neurodegeneration (PKAN) and PLA2G6-Associated Neurodegeneration (PLAN): Revi ...; 1. Introduction; 2. Pantothenate Kinase-Associated Neurodegeneration; 2.1. Clinical presentation; 2.1.1. Onset of clinical symptoms; 2.1.2. Clinical disease features; 2.1.3. Disease course; 2.2. Neuroimaging features in PKAN (Fig.2.1); 2.3. Neuropathological features of PKAN; 2.4. Molecular genetics of PKAN; 2.5. Pathophysiological disease mechanisms in PKAN
2.6. Management of PKAN treatment2.6.1. Clinical assessment; 2.6.2. Treatment strategies; 2.6.3. Spasticity and dystonia; 2.6.4. Multidisciplinary team input; 2.6.5. New experimental therapies under consideration (see Chapter 7); 2.6.5.1. Iron chelation (see Chapter 7); 2.6.5.2. Pantothenate; 3. PLA2G6-Associated Neurodegeneration; 3.1. Clinical features of PLAN; 3.1.1. Disease onset; 3.1.2. Disease clinical features; 3.1.3. Disease course; 3.1.4. Electrophysiological investigations in PLAN; 3.2. Neuroimaging features of PLAN (Fig.2.3); 3.3. Neuropathological features of PLAN
3.4. Molecular genetic features of PLAN3.5. Pathogenic disease mechanisms in PLAN; 3.6. Management of PLAN; 3.6.1. Clinical assessment; 3.6.2. Multidisciplinary team input; 3.6.3. New experimental therapies under consideration (see Chapter 7); 3.6.4. PLA2G6-dystonia parkinsonism; 3.6.5. Treatment strategies; 3.6.5.1. For INAD and atypical NAD; 4. Conclusion; Acknowledgments; References; Chapter Three: Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN); 1. Introduction; 2. Clinical Findings; 3. Neuroimaging; 4. Neuropathology; 5. Genetics; 6. Conclusion; Acknowledgments
edited by Kailash P. Bhatia and Susanne A. Schneider.
Includes bibliographical references and index.
International review of neurobiology ; v. 110